Pathway inactivation leads to YAP1/TAZ nuclear accumulation, where they interact with multiple oncogenic pathways (NOTCH, MAPK, Wnt) to drive stemness, EMT, drug resistance, and tumor progression (405–408). Here, YAP1 is linked to neoplasm.